Akebia Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 167
- Market Cap
- $319.6M
- Website
- http://www.akebia.com
- Introduction
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: AKB-6548 (therapeutic dose)Drug: PlaceboDrug: AKB-6548 (supratherapeutic dose)
- First Posted Date
- 2014-02-13
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT02062203
20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia
- First Posted Date
- 2013-07-24
- Last Posted Date
- 2022-07-21
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 210
- Registration Number
- NCT01906489
42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 93
- Registration Number
- NCT01381094
Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia
- First Posted Date
- 2010-11-08
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 10
- Registration Number
- NCT01235936
© Copyright 2025. All Rights Reserved by MedPath